Type 1 Diabetes Vaccine: Does Diamyd Have a Winning Formula?
XTalks
SEPTEMBER 15, 2020
A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. The trial showed a preservation of function of insulin-producing ?-cells cells at 15 months post-diagnosis. cells (see video above).
103 
Let's personalize your content